Trial Design: Open-label, multicentre phase 1b study of ATRA (retinoic acid) administered with gemcitabine and nab-Paclitaxel. There are two parts to this study: A dose-escalation part in untreated advanced pancreatic cancer patients to determine the maximum tolerated dose and a dose expansion part to determine the optimal biological dose.
This study stems from research carried out by Prof H. Kocher and his team at Barts Cancer Institute.
Trial Chairman & Co-Chief Investigator: Prof H. Kocher
Chief Investigator: Dr S Slater
Trial contact: email@example.com
Clinical Trials.gov: NCT03307148
Sponsor: Barts Health NHS Trust
Participating countries: UK
Source of funding: MRC (funding), Celgene (funding and study drug)
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Kocher, H.M., Basu, B., Froeling, F.E.M. et al. Nat Commun 11, 4841 (2020).